Exelixis (EXEL) Capital Expenditures (2010 - 2026)
Exelixis (EXEL) posted quarterly Capital Expenditures of $1.5 million for Q2 2026, down 48.88% year-over-year from $3.0 million in Q2 2025, and up 30.42% quarter-over-quarter from $1.2 million in Q1 2026.
Analysis
Exelixis (EXEL) Capital Expenditures (2010 - 2026) Analysis & Trends
Exelixis' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.5 million for Q2 2026.
- In Q2 2026, Capital Expenditures fell 48.88% year-over-year to $1.5 million; the TTM figure through Apr 2026 stood at $7.0 million (down 67.8% YoY), while the FY2026 annual figure was $8.4 million, down 70.36% from the prior year.
- Capital Expenditures for Q2 2026 stood at $1.5 million, up from $1.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $13.1 million in Q4 2023, with the low at $1.2 million in Q1 2026.
- The 5-year median for Capital Expenditures is $5.9 million (2023), against an average of $6.3 million.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures surged 117.62% in 2022, then plunged 81.92% in 2025.
- Exelixis' Capital Expenditures stood at $9.7 million in 2022, then surged by 35.18% to $13.1 million in 2023, then sank by 37.59% to $8.2 million in 2024, then slumped by 81.92% to $1.5 million in 2025, then rose by 1.82% to $1.5 million in 2026.
- Business Quant data shows EXEL's Capital Expenditures at $1.5 million in Q2 2026, $1.2 million in Q1 2026, and $1.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 6.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 6.82 Mn |
| Apr 3, 2026 | 1.51 Mn |
| Jan 2, 2026 | 1.16 Mn |
| Oct 3, 2025 | 1.48 Mn |
| Jul 4, 2025 | 2.84 Mn |
| Apr 4, 2025 | 2.95 Mn |
| Jan 3, 2025 | 3.98 Mn |
| Sep 27, 2024 | 8.20 Mn |
| Jun 28, 2024 | 6.57 Mn |
| Mar 29, 2024 | 9.69 Mn |
| Dec 29, 2023 | 13.14 Mn |
| Sep 29, 2023 | 9.37 Mn |
| Jun 30, 2023 | 5.94 Mn |
| Mar 31, 2023 | 12.02 Mn |
| Dec 30, 2022 | 9.72 Mn |
| Sep 30, 2022 | 5.04 Mn |
| Jul 1, 2022 | 7.34 Mn |
| Apr 1, 2022 | 5.61 Mn |
| Dec 31, 2021 | 5.96 Mn |
| Oct 1, 2021 | 14.50 Mn |